Miragen Therapeutics, Inc. Banner Image

Miragen Therapeutics, Inc.

  • Ticker MGEN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Miragen Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Boulder, Colorado
miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen’s clinical product candidate for the treatment of certainMore cancers, cobomarsen, is an inhibitor of miR-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for miR-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. MRG-110, an inhibitor of miR-92, is miRagen’s product candidate for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates.
Miragen Therapeutics, Inc.

Most Recent Annual Report

Miragen Therapeutics, Inc.
MOST RECENT 2019 Form 10K